Fluorobiotech was honored to present at the Global Partners Meeting of the WHO / Medicines Patent Pool (MPP) mRNA Vaccine Technology Transfer Program, a landmark event that brought together manufacturers, policymakers, and researchers from over 15 countries committed to building mRNA vaccine manufacturing capacity in low- and middle-income countries (LMICs).
Hosted by the Medicines Patent Pool (MPP) under the auspices of the World Health Organization (WHO), the meeting convened key stakeholders from the South African mRNA Vaccine Consortium (SAMVAC), including innovation leaders such as Afrigen Biologics, Biovac, and Wits University.
As part of this global program, Fluorobiotech presented its pioneering work in advancing the local production of high-performance recombinant in vitro transcription (IVT) enzymes — a critical component in the manufacture of mRNA vaccines. Through its patented SelfPrep technology, the company is working to solve one of the most persistent bottlenecks in the vaccine supply chain: the high cost, import-dependent availability of raw materials essential for mRNA production.
“We are proud to contribute to a program that is not only reshaping vaccine equity, but also empowering LMICs to lead their own biomanufacturing futures,” said Dr. Du Preez van Staden, CEO of Fluorobiotech. “Our work focuses on building sustainable access to enzyme inputs that meet global performance and quality standards.”
Fluorobiotech also highlighted its strategic partnership with the Stellenbosch University Biofoundry, its lead academic collaborator. Together, they are developing scalable quality control and validation services for enzyme products — a critical step in ensuring regulatory readiness, reproducibility, and GMP-compliance across the African mRNA value chain.
The WHO / MPP mRNA Vaccine Technology Transfer Program is an ambitious initiative that seeks to democratize access to life-saving vaccines and therapeutics by enabling LMICs to develop open, non-exclusive manufacturing capabilities, with a strong emphasis on training, technology transfer, and supply chain localization.
Fluorobiotech expresses its deepest thanks to the WHO, Medicines Patent Pool, and SAMVAC for their continued support and shared vision of a health-secure, innovation-driven Africa.